Detail akcie Allergy Ther online

Business Summary: Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Allergy Therapeutics plc revenues decreased less than 1% to L55M. Net loss increased 4% to L40.1M. Revenues reflect Rest of World (including UK) segment increase of 12% to L4.1M, Italy/Spain/Southern Europe segment increase of 3% to L12.7M, also reflect Germany/Central Europe segment decrease of 2% to L38.2M.